Results 61 to 70 of about 431,140 (262)

Long‐Term Outcomes of Patients With Relapsed/Refractory Neuroblastoma Treated on ANBL1221: A Report From the Children's Oncology Group

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Results of COG ANBL1221 changed treatment paradigms for patients with relapsed/refractory neuroblastoma. Chemoimmunotherapy with irinotecan/temozolomide/dinutuximab is now used as both bridge therapy following suboptimal response to induction and as treatment in first relapse.
Elizabeth Sokol   +6 more
wiley   +1 more source

Dyspepsia in the middle ages: a reference in Giovanni Boccaccio's Decameron (14th century AD)? [PDF]

open access: yesActa Biomed, 2023
Galassi FM   +5 more
europepmc   +1 more source

BMT4me En Español: Multisite Feasibility and Usability Testing of a Spanish‐Language mHealth Adherence Support App for Spanish‐Speaking Caregivers of Children After Hematopoietic Stem Cell Transplantation and Cancer Treatment

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Medication nonadherence during the first 100 days after pediatric hematopoietic stem cell transplantation (HSCT) and during oncology treatment increases risk for complications. BMT4me is a caregiver‐facing mobile health (mHealth) application providing medication reminders, symptom tracking, and note‐taking features to support ...
Micah A. Skeens   +4 more
wiley   +1 more source

Presentazione [PDF]

open access: yesParole Rubate, 2019
Introduction
Francesco Bonelli   +2 more
doaj  

Measurable Residual Disease Monitoring During Treatment for Pediatric Acute Myeloid Leukemia in First Relapse

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Survival after relapse in pediatric acute myeloid leukemia (AML) remains poor, highlighting the critical importance of identifying prognostic factors to guide optimal relapse management. Methods We investigated the prognostic impact of multiparameter flow cytometry (MFC) measurable residual disease (MRD) in 188 patients with first ...
Camilla Poulsen   +21 more
wiley   +1 more source

Comic Books Featuring the Middle Ages

open access: yesItinéraires, 2010
This article explores comic books that feature the Middle Ages as a way to show how the study of this popular media can help to further the research of the modernity of the Middle Ages.
Mónica Ann Walker Vadillo
doaj   +1 more source

T2* Magnetic Resonance Imaging Uncovers Hemosiderin Burden in Pediatric Hemophilia: A Call for Sensitive Imaging Biomarkers

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Hemophilic arthropathy remains the leading morbidity in hemophilia despite modern prophylaxis, and early joint damage may be missed by routine exams. This study explored T2* MRI as a noninvasive biomarker of hemosiderin deposition in pediatric hemophilia.
Jessica Garcia   +6 more
wiley   +1 more source

India Traders of the Middle Ages

open access: yesAmerican Journal of Islam and Society, 2009
Throughout Antiquity, the Middle Ages, and our current era, the Indian Ocean has been the economic backbone of an interconnected global community. This inter-territorial commerce, which feeds a vast network of merchants from the western Mediterranean to ...
Isa Blumi
doaj   +1 more source

Ancestry and kinship in a Late Antiquity-Early Middle Ages cemetery in the Eastern Italian Alps. [PDF]

open access: yesiScience, 2023
Coia V   +6 more
europepmc   +1 more source

Survival by Race and Ethnicity in Children and Adolescents/Young Adults With Relapsed/Refractory Hodgkin Lymphoma: A Pooled Analysis of Children's Oncology Group Trials

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Purpose Despite 5‐year survival rates of over 90% among children and adolescents/young adults (CAYAs) with classic Hodgkin lymphoma (cHL), 15%–20% relapse after frontline therapy. Prior analysis of frontline Children's Oncology Group (COG) clinical trials demonstrated that, despite similar rates of relapse, non‐Hispanic Black (NHB) and ...
Mallorie B. Heneghan   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy